Corient Private Wealth’s Nautilus Biotechnolgy NAUT Stock Holding History

Corient Private Wealth’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$308K	Buy	164,788 +50,000	+44%	+$132K	﹤0.01%	2546
2026 Q1	$445K	Hold	114,788	–	–	﹤0.01%	2096
2025 Q4	$224K	Sell	114,788 -204,352	-64%	-$335K	﹤0.01%	2364
2025 Q3	$270K	Sell	319,140 -116,210	-27%	-$85.4K	﹤0.01%	2190
2025 Q2	$316K	Buy	435,350 +390,000	+860%	+$293K	﹤0.01%	1960
2025 Q1	$39K	Hold	45,350	–	–	﹤0.01%	2237
2024 Q4	$76.2K	Hold	45,350	–	–	﹤0.01%	2248
2024 Q3	$129K	Hold	45,350	–	–	﹤0.01%	2290
2024 Q2	$106K	Buy	+45,350	New	+$118K	﹤0.01%	2207
2023 Q4	–	Sell	-45,350	Closed	-$143K	–	2318
2023 Q3	$143K	Buy	+45,350	New	+$148K	﹤0.01%	1981
2023 Q1	–	Sell	-45,350	Closed	-$81.6K	–	2041
2022 Q4	$81.6K	Buy	+45,350	New	+$87.5K	﹤0.01%	1589

Other funds holding NAUT

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CFM

Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Corient Private Wealth's NAUT Position: Q2 2026 in Review

Corient Private Wealth increased its Nautilus Biotechnolgy (NAUT) stake by 44% in Q2 2026, buying an estimated $132K and bringing the position to 164,788 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #2546.

Corient Private Wealth first reported a position in NAUT in Q4 2022 and has held it in 11 quarters since. The position peaked at $445K in Q1 2026. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

Corient Private Wealth held 164,788 shares of Nautilus Biotechnolgy worth $308K as of Q2 2026.
Corient Private Wealth bought 50,000 Nautilus Biotechnolgy shares in Q2 2026, an estimated $132K.
Nautilus Biotechnolgy made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2546 holding.
Corient Private Wealth first reported a position in Nautilus Biotechnolgy in Q4 2022 and has held it in 11 quarters since.
Corient Private Wealth's Nautilus Biotechnolgy position peaked at $445K in Q1 2026.
93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.